According to the latest report by IMARC Group, titled “Left Atrial Appendage Closure Devices Market Report by Product (Endocardial LAA Devices, Epicardial LAA Devices), End User (Hospitals, Ambulatory Surgery Centers, and Others), and Region 2025-2033,” the global left atrial appendage closure devices market size reached USD 1.7 Billion in 2024. Left atrial appendage closure (LAAC) devices are medical implants that prevent strokes among patients with atrial fibrillation, a common heart rhythm disorder. They are designed to seal off this area, which reduces the risk of clots escaping and causing blockages in the brain. They can be performed by a specialist using catheterization techniques. They offer an alternative to long-term blood-thinning medication, which makes them a valuable option for those who cannot tolerate such drugs, and prevents the formation and migration of clots. They have been effective in stroke prevention and have become an essential tool in cardiac care.
Global Left Atrial Appendage Closure Devices Market Trends:
The increasing number of atrial fibrillation cases among the masses and the rising older population that is more susceptible to heart diseases represent one of the major factors driving the demand for LAAC devices around the world. Moreover, the growing awareness and education among people about atrial fibrillation and LAAC solutions are influencing the market positively. In addition, the increasing number of clinical trials that prove the efficacy of LAAC devices and the ongoing research and development (R&D) activities by key players are augmenting the market growth. Apart from this, the growing adoption of LAAC devices to provide a minimally invasive surgical (MIS) procedure alternative to long-term medication, which makes them preferable for many patients, is creating a positive outlook for the market. Looking forward, the market value is projected to reach USD 6.7 Billion by 2033, expanding at a CAGR of 16.17% during 2025-2033.
Market Summary:
Report Features | Details |
---|---|
Base Year of the Analysis | 2024 |
Historical Period | 2019-2024 |
Forecast Period | 2025-2033 |
Units | Billion USD |
Products Covered | Endocardial LAA Devices, Epicardial LAA Devices |
End Users Covered | Hospitals, Ambulatory Surgery Centers, Others |
Regions Covered | Asia Pacific, Europe, North America, Latin America, Middle East and Africa |
Countries Covered | United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico |
Companies Covered | Abbott Laboratories, AtriCure Inc., Boston Scientific Corporation, Cardia Inc., Lepu Medical Technology (Beijing) Co. Ltd., LifeTech Scientific, etc. |
Customization Scope | 10% Free Customization |
Post-Sale Analyst Support | 10-12 Weeks |
Delivery Format | PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request) |
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC Group
134 N 4th St.
Brooklyn, NY 11249, USA
Email: Sales@imarcgroup.com
Americas:- +1 631 791 1145 | Africa and Europe :- +44-753-713-2163 | Asia: +91-120-433-0800